A previous study showed that semaglutide, a diabetes drug marketed under the names Wegovy or Ozempic, could reduce the risk of heart attack or stroke.
This time, researchers have demonstrated that this drug, which stimulates insulin production and lowers blood sugar levels, would also reduce the risk of kidney failure.
A reduction in the risk of kidney failure by 16%
To achieve this assertion, researchers from the George Institute in Sydney (Australia) carried out a meta-analysis of 11 large-scale clinical trials involving 85,373 people suffering from diabetes or chronic kidney disease.
The results show that semaglutide drugs used for 24 weeks reduced the risk of kidney failure by 16% and worsening kidney function by 22% compared to a placebo. Additionally, the analyzes confirmed what previous studies had shown: the rate of death from all causes was 13% lower in patients treated with GLP-1 receptor agonists.
Source : Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trialNature medicine, November 2024
Source: www.topsante.com
